Background. Pancreas transplantation in complicated type 1 (insulin dependent) diabetes mellitus improves the quality of life, increases longevity and stabilizes diabetic complications. There may be clinician reticence due to perceived poor outcomes with published associated mortality rates of 5-8% due to significant co-morbidities, particularly cardiovascular impairment. Methods. Retrospective analysis was performed on patients undergoing pancreas transplantation in a single centre since the programme's initiation [simultaneous pancreas kidney (SPK) = 148, pancreas after kidney (PAK) = 33 and pancreas transplant alone (PTA) = 11] compared with a control group accepted contemporaneously onto the waiting list. The primary endpoint was patient mortality. The risk factors including medical and diabetic history, demographics, transplant type and waiting time were analysed. Results. The waiting list mortality was 30% (35 of 120) compared with a mortality of 9% (20 of 193) post-transplantation (P < 0.001). Deaths on the waiting list compared with transplantation up to 1 year had a relative risk of 2.67 (95% CI: 0.81-3.51; P = 0.19), whilst those surviving >1 year had a
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I N T R O D U C T I O N
Diabetes mellitus is a significant financial stressor on modern healthcare provision accounting for >8% of the total health budget [1, 2] . Intensive insulin therapy delays the progression of secondary complications, thereby decreasing mortality in type 1 (insulin dependent) diabetes [3] . This assumes importance as life expectancy in patients is reduced by up to 15 years predominantly due to cardiovascular disease [4, 5] .
Pancreas transplantation for the treatment of type 1 diabetes was first described in 1966 [6] . Historical concerns still exist regarding this procedure as it has the highest complication rate of any abdominal transplant procedure and is initially associated with dismal graft and patient survival [7, 8] . It has, however, undergone significant refinement due to the effects of the 'learning curve' for this procedure, as well as improvements in the surgical technique and immunosuppression and now consistently offers benefit in comparison to alternative treatment modalities [3, 4, 9, 10] . Patient longevity is predominantly improved by decreased progression of coronary atherosclerosis [11] [12] [13] .
Between 2000 and 2004, the International Pancreas Transplant Registry reported 1-year patient survival after pancreas transplantation of 95, 95 and 98% for simultaneous pancreas kidney (SPK), pancreas after kidney (PAK) and pancreas transplant alone (PTA), respectively, whilst single-centre reports vary between 92 and 98% [7, [14] [15] [16] [17] . These figures remain excellent despite patients with severe co-morbidities, particularly cardiovascular impairment, and reflect improved pre-operative assessment. Mortality from cardiovascular disease remains 2-to 8-fold higher in persons with diabetes mellitus compared with the general population [4] . This suggests that critical patient selection and comprehensive evaluation potentially minimize serious adverse effects and improve outcomes [18] .
Pancreas transplantation is performed in three distinct categories according to native renal function: SPK transplant in patients with end-stage renal failure (ESRF); PAK transplant in previously kidney-only transplanted diabetics (80 and 10% of transplants, respectively) and a PTA in patients with severe diabetes without renal impairment.
Enhanced patient survival due to pancreas transplantation remains poorly understood compared with established insulin therapies, either through glycaemic control or through insulin pumps. Venstom demonstrated a survival benefit with solid organ pancreas transplantation albeit only in patients with preserved renal function [19] . A comparison was, therefore, made on survival of pancreas recipients with that of a control group of similar patients, regarding both cardiovascular reserve and secondary diabetic complications, on the waiting list for pancreas transplantation with both intact and impaired renal function at a single institution. This control group closely replicated the demographic and co-morbid characteristics, especially cardiovascular, of patients undergoing transplantation. In addition, the criteria for time on the waiting list are not proportional to the severity of type 1 diabetes or secondary complications, but rather relates to the genetic haplotype and blood group. This approach closely replicates previous statistical models generated in other solid organ transplants [20, 21] . This study aimed to address whether solid organ pancreas transplantation provides definitive and consistent survival advantage over continued medical therapies and optimization for type 1 diabetes, especially in ESRF.
M AT E R I A L S A N D M E T H O D S
A retrospective cohort study was used to determine the mortality rates between pancreas transplant recipients and a control group with similar co-morbidities active on the waiting list who did not undergo surgery, utilizing patient mortality as a primary endpoint. Patients undergoing suspensions on the waiting list for medical reasons requiring intervention were excluded from analysis, thereby minimizing randomization bias. Short periods of infective illness requiring no intervention did not mandate exclusion from the waiting list group. In the period between the inception of the pancreas transplant programme in the said unit in June 2001 and December 2009, 312 patients were placed on the waiting list. All recipients were evaluated in accordance with previously published guidelines [22] . One hundred and ninety-two patients underwent transplantation (SPK = 148, PAK = 33 and PTA = 11), whilst 120 patients remained on the waiting list without surgery (Figure 1 ). The cohorts included all patients who were listed for SPK, PAK or PTA. Clinical data were analysed, statistically evaluated and compared between these two groups. Data included both recipient's and waiting list patient's mortality rates from the time of activation on the waiting list for both groups (1 year and overall mortality) and the time to death as primary endpoints. In addition, patient demographics, duration and history of diabetes, dialysis duration in patients with associated renal impairment and significant other medical history were collected. Cardiological risk factors, both subjective symptomatology and objective cardiac testing [echo testing, myocardial perfusion scans and observed ejection fractions (%)], were also noted.
Transplant protocol
The criteria utilized by individual transplant units for acceptance onto the waiting list for pancreas transplantation in the UK are governed by national guidelines produced by NHS Blood and Transplant and derived from European Best Practice Guidelines and include full cardiological assessment of physiological reserve prior to activation [23] . Patients were allocated organs from the waiting list based on the blood group and human leucocyte antigen matching and wait time.
Pancreas implantation was undertaken as previously described [24] . The immunosuppressive regimen included induction therapy with basiliximab (Simulect ® , Novartis, East Hanover, NJ) and methylprednisolone (Solu-Medrone ® , Pfizer, New York,) [25] . Maintenance immunosuppression and postoperative care were as previously described [24] .
Statistical analysis
All data were prospectively or contemporously collected and retrospectively analysed. Descriptive and univariable statistical analyses were performed. Survival was calculated from the time of transplant waiting list activation to death or end of the study period. Demographic data, mortality rates and associated medical risk factors (cardiological and renal) are given as mean (SD) or median (range) values. A Fisher's exact test was used for survival comparison, analysis of dialysis requirement as well as history of previous myocardial infarction. A non-parametric Mann-Whitney U-test was conducted for comparison of duration of type 1 diabetes, insulin requirements, number of diabetic complications as well as duration of dialysis. An unpaired t-test was utilized for comparisons of age at transplant listing. A Kaplan-Meier curve was constructed for survival analysis. The relative risk was calculated as the ratio of death occurring in the waiting list group in comparison to those patients undergoing transplantation for all analyses, P < 0.05 was considered statistically significant. Statistical calculations were performed using SPSS ® version 18.0 statistical software (SPSS, Chicago, IL). ]. This resulted in a total of 120 patients who remained on the waiting list for transplantation (Tables 1 and  2 ). The median waiting time for the cohort of patients who received a transplant was 274 days (range 6-2211) days. At the time of implantation, 65 patients had bladder drainage, whilst the remainder had enteric drainage of exocrine secretions, with the former occurring at clinician discretion during the programme's initiation.
R E S U LT S

Mortality and relative risk
Mortality for patients undergoing pancreas transplantation was collated and compared with deaths on the waiting list. Patients who underwent transplantation had an overall noted mortality (mortality at any time point) of 10% (20 of 192) compared with a total mortality of 30% (35 of 120) on the waiting list (P < 0.001; Fisher's exact test). One-year mortality after listing was 4% (8 of 192) for the transplant group compared with 13% (16 of 120) on the waiting list (P < 0.0001; Fisher's exact test) as demonstrated by survival curves for the 2-year period following waiting list activation (Figure 2 ). This demonstrated equivalent survival in the initial post-operative period compared with the waiting list with overall benefits exhibited over longer time points. In addition, survival benefits were shown across all three groups in total and at 1 year including isolated pancreas transplantation (SPK, PAK and PTA) although the low numbers of this subset analysis precluded statistical significance (Table 3) .
Deaths on the waiting list up to 1 year compared with those following transplantation (including the waiting period for surgery) had a relative risk of 2.67 (95% CI: 0.81-3.51; P = 0.19). Patients surviving >1 year had a relative risk of 5.89 of dying on the waiting list (95% CI: 1.70-3.20; P < 0.0005) with an overall relative risk of 2.8 of waiting list mortality (95% CI: 1.47-3.10; P < 0.0001). This correlated with the noted overall death rates for the two distinct groups. One-year pancreas graft survival over this period was 70% (30 of 43) for pancreas-alone grafts and 81% (120 of 149) for SPKs. Overall graft survival was 78% (150 of 192).
Potential confounding factors
In order to ensure that potential medical and cardiological risk factors did not account for difference in mortality risk F I G U R E 1 : Outcomes of patients undergoing transplant assessment and acceptance onto the waiting list for pancreas solid organ transplantation over a 9-year period. This demonstrates that patients accepted onto the list either underwent transplantation, remain on the waiting list or have died in the intervening period on the waiting list. 
O R I G I N A L A R T I C L E
M o r t a l i t y i n d i a b e t e s a n d p a n c r e a s t r a n s p l a n t a t i o n between the two groups, potential confounding factors were quantified and compared ( Table 4 ). The nature of type 1 diabetes and its complications, associated cardiovascular risk factors and nature and duration of ESRF were compared. Demographic differences examined included age and sex differences as well as time from listing and death and neither demonstrated any statistical differences. All patients in both the groups suffered from type 1 diabetes with no cases of noninsulin-dependent (type 2) diabetes mellitus with comparable duration of disease in both groups.
The occurrence and number of diabetic complications were also compared and established at transplant listing to ensure consistency of reporting. These included the presence of nephropathy (glomerular filtration rate <30 mL/min), retinopathy (confirmed by specialist ophthalmologist and requiring therapeutic intervention), lower limb ulceration or Charcot joint, vasculopathy, hypoglycaemic unawareness, autonomic dysfunction or neuropathy. There were again no differences in either group. However, all patients who died in either group had associated nephropathy emphasizing the negative impact of ESRF on survival.
The requirement for renal replacement therapy (dialysis) in established ESRF clearly has important ramifications, particularly with regard to altered life expectancy, perioperative mortality as well as magnitude of operation as patients will require a PAK or SPK transplant. Patients who died following transplantation tended to have required dialysis in more cases although this only approached statistical significance (42 versus 70%; P = 0.09, Fisher's exact test). Dialysis did, however, tend to be of a shorter duration in the mortality following transplantation group (P = 0.63).
Cardiological risk factors and pre-existing myocardial events are also important as a potential confounder on the outcome. Two patients who died whilst active on the transplant waiting list (6%) had confirmed evidence of a previous F I G U R E 2 : Kaplan-Meier survival curves comparing deaths on the waiting list with mortality after pancreas transplantation for 2 years following activation on the waiting list. This demonstrated equivalent survival in the initial postoperative period compared with the waiting list with an overall benefit being exhibited over longer time points. This accounts for the fact that patients undergoing transplantation would inevitably demonstrate early survival benefits as they would by necessity have no mortality while on the waiting list. However, it still demonstrates considerable improvements at later time points. There were no other quantifiable differences across the two groups in terms of cardiovascular risk factors. In the transplanted group, two patients had had previous transient ischaemic attacks (TIAs) and there had been one previous myocardial infarction while the waiting list group had one patient who had had a previous TIA (P = NS). Data regarding glycaemic control, blood pressure and lipid levels did not demonstrate any differences either within or between the two groups and have not been shown in the analysis.
D
Age at death
Previous data have suggested that transplantation in younger age groups may result in decreased mortality rates (8% in those <50 years old and 12% in those >50 years at transplantation) [24] . A comparison was, therefore, also made of average time from listing to death in patients less and older than ∼50 in our cohort to corroborate previous findings. Patients <50 years who died, either on the waiting list or the post-transplant, had a median interval of 417 ± 79.7 days (range between assessment and death. In contrast, for patients who were >50, the median interval was 478 ± 145.7 days (range 2-2525) although the small number of patients in each group precluded statistical significance (P = 0.45).
Cause of death
The cause of mortality in each group is of interest as the deleterious effects of type 1 diabetes particularly on the cardiovascular system play a significant contributing factor. In addition, the perceived high perioperative morbidity associated with pancreas transplantation may have a significant impact on mortality. Eleven of the 35 deaths in the waiting list mortality group were unable to be ascribed to any particular cause despite attempts to obtain information from local hospitals, general practitioners or national regulatory bodies (National Health Service Blood and Transplant). This reflects local practise with many patients attending for assessment from geographically disparate areas. Subsequently, outcome analysis was only performed in 24 patients. Forty-one percent (10 of 24) of recorded deaths in the waiting list mortality group were ascribed to cardiological events (myocardial infarctions), whilst the highest proportion in the post-transplant group were from sepsis (five patients; primarily immunosuppression related) and haemorrhage (seven patients; all mycotic aneurysm formation) ( Table 5 ). These two events were both statistically significant (P = 0.03 and P = 0.01, respectively; Fisher's exact test). 
O R I G I N A L A R T I C L E
M o r t a l i t y i n d i a b e t e s a n d p a n c r e a s t r a n s p l a n t a t i o n
D I S C U S S I O N
Pancreas transplantation for treatment of type 1 diabetes has evolved significantly since its inception. Despite this, perceptions amongst some clinicians have remained unchanged with misconceptions regarding unacceptably high mortality and morbidity rates. This may result in reticence to promote transplantation to potential suitable recipients, contributing to unnecessarily poor outcomes in some diabetic patients. These data aimed to establish whether the risk of mortality outweighed the potential benefits to type 1 diabetic patients sufficiently healthy to benefit from solid organ transplantation, as it remains an aggressive disease with significant morbidity and mortality [26] . This was corroborated with an overall mortality rate of 30% and a 1-year mortality rate of 13% for patients deemed to be fit for transplantation, but not allocated a suitable organ from the donor pool due to organ allocation and correlated with previously published data on type 1 diabetic patients not transplanted [27] . However, they compared unfavourably with 1-year and overall mortality rates of 4 and 9%, respectively, in the cohort. This corresponds well with the published rates, especially in the latter half of the series, and includes potential deleterious effects of the 'learning curve' as well as numerous innovations including the first national use of a DCD donor and synchronous live kidney with pancreas transplantation, in addition to transplantation in a significant proportion of elderly recipients [28, 29] .
This study represents the first observation of mortality in patients with both type 1 diabetes and ESRF. The number of deaths on the waiting list exceeded those undergoing surgery despite these patients having a greater proportion of renal function sparing, emphasizing transplantation's advantages. The data are further strengthened by the absence of any potential confounding factors which could potentially discriminate between these two groups of patients. Mortalities on the waiting list were observed in a younger group with a shorter duration of type 1 diabetes, implying a more aggressive disease presentation in this cohort. These data mandate a more aggressive policy of transplant consideration for young patients fulfilling the strict selection criteria [24] .
The predominant cause of waiting list patient deaths was cardiovascular, whilst in the transplant group it was largely infective and immunosuppressive complications. Improvements in the operative technique over the programme's evolution as well as more focused immunosuppressive tailoring have resulted in improved outcomes. The optimization of cardiovascular risk factors in type 1 diabetes has historically proven to be a greater challenge for clinicians in disease management [4, 5] .
This study represents the first examination comparing the outcomes in patients both with and without renal impairment and, therefore, represents a heterogeneous group of surgical procedures (SPK, PAK and PTA). The low level of mortality suggests that the survival benefits of solid organ transplantation in type 1 diabetes can be extended to those patients with ESRF in addition to previously reported benefits [19] . The low number of patients with normal renal function (PAK and PTA) due to the low numbers of patients in both groups as per most unit's clinical activities, however, limit wide ranging conclusions without continued longitudinal recruitment of patients for comparison.
The retrospective nature of data collection undoubtedly limits the power of this cohort study. One of our concerns in trying to establish the mortality risk for each distinct form of solid organ pancreas transplantation was that in performing subset analysis, the diminishing numbers from sub-classification, due to the inherent limitations of a single-centre retrospective trial, would nullify any perceived statistical significance due to potential type 1 errors. The method of utilizing patients on the waiting list as a comparator group represents the best available control method due to ethical concerns with treatment arm allocation in these circumstances. However, this method does have limitations in that the groups may not be equivalent as patients who are medically unfit may not undergo transplantation. This has been limited by including only patients from the waiting list who were not suspended due to reasons of requiring medical 
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intervention, thereby ensuring selection of a more comparable group of patients. In addition, the absence of any differences in confounding factors demonstrated equivalence across the two groups. Echocardiography data were used as the most objective comparator for cardiological investigations. Due to the retrospective nature of the cohort coupled with the wide geographical variations of the patients, patients had a wide variability in timing and types of investigations precluding any comprehensive comparative data being available.
Further studies might include a prospective trial of outcomes subsequent to transplant listing. In addition, a randomized trial comparing different modalities of type 1 diabetes treatment could be considered although treatment arm randomization and comparators may make this technically and ethically difficult. A comparison of outcomes for 'good quality' deceased donor kidney compared with pancreas transplantation is required but outside the remit of this dataset due to data limitations of a single-centre retrospective analysis. Registry data or a prospective trial to particularly answer this question may be required.
Early negative clinical outcomes in solid organ pancreas transplantation have undoubtedly resulted in potential treatment allocation bias for involved clinicians. This may have resulted in understandable reticence to propose the option of solid organ transplantation in patients, particularly those with concomitant renal impairment, who may in reality benefit from this as an optimum treatment modality, with resultant sub-optimal medical management of this condition. However, our data suggest that transplantation offers both qualitative and quantitative benefits in terms of life expectancy for these patients. This offers a definitive improvement in 'best medical therapy' for type 1 diabetes. Solid organ pancreas transplantation, particularly for patients with renal impairment, should be defined as the definitive and optimal treatment option in appropriate cases of type 1 diabetes.
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